CD274 and cancer: For various cancers, six FDA-approved PD-L1 inhibitors are now available: PD-1 inhibitor antibodies nivolumab, pembrolizumab, cemiplimab, and PD-L1 inhibitor antibodies atezolizumab, avelumab, and durvalumab [13,14].